Open $22.65
Day Range 22.59 - 22.95
52 Week Range 15.35 - 23.92
Market Cap $3.64B
Shares Outstanding 160.45M
Public Float 158.66M
Beta 0.99
Rev. per Employee $462.70K
P/E Ratio N/A
EPS -$0.59
Yield N/A
Dividend N/A
Ex-Dividend Date N/A
Short Interest 11.28M 05/14/21
% of Float Shorted 7.11%
Average Volume 1.5M

5 Day	2.39%
1 Month	2.44%
3 Month	18.07%
YTD	13.63%
1 Year	36.32%

Sell
Under
Hold
Over
Buy

Number of Ratings 11 Full Ratings

MarketWatch
Dow Jones

Alkermes stock halted for news pending

Jun. 1, 2021 at 7:00 a.m. ET by Tomi Kilgore

Barron's

AbbVie Is Mizuho’s Top Pick Among Large-Cap Biopharma Stocks

Jan. 7, 2021 at 8:45 a.m. ET by Barron's

Alkermes upgraded to buy from neutral at Mizuho

Oct. 15, 2020 at 6:35 a.m. ET by Tomi Kilgore

Alkermes stock price target raised to $24 from $19 at Mizuho

Oct. 15, 2020 at 6:04 a.m. ET by Tomi Kilgore

Barron's

Alkermes Reported More Revenue Than Expected. Here’s Why the Stock Is Falling.

Feb. 14, 2020 at 10:46 a.m. ET by Barron's

Alkermes stock price target cut to $20 from $31 at BofA Securities

Feb. 14, 2020 at 10:40 a.m. ET by Tomi Kilgore

Alkermes downgraded to neutral from buy at BofA Securities

Feb. 14, 2020 at 10:40 a.m. ET by Tomi Kilgore

Alkermes stock price target cut to $21 from $25 at J.P. Morgan

Feb. 14, 2020 at 7:52 a.m. ET by Tomi Kilgore

Alkermes downgraded to neutral from overweight at J.P. Morgan

Feb. 14, 2020 at 7:51 a.m. ET by Tomi Kilgore

FDA told Alkermes to stop publishing Vivitrol ad

Dec. 11, 2019 at 12:12 p.m. ET by Jaimy Lee

Alkermes to acquire Rodin Therapeutics for up to $950 million

Nov. 18, 2019 at 7:30 a.m. ET by Ciara Linnane

Biogen shares fall 3%

Nov. 14, 2019 at 3:08 p.m. ET by Jaimy Lee

Barron's

Biogen’s Alzheimer’s Drug Could Be a Winner. One Analyst Recommends the Bet.

Oct. 30, 2019 at 10:34 a.m. ET by Barron's

Biogen's and Alkermes' Vumerity gets FDA approval for MS; Biogen's stock surges

Oct. 30, 2019 at 7:40 a.m. ET by Tomi Kilgore

Biogen, Alkermes MS treatment Vumerity gets FDA approval

Oct. 30, 2019 at 7:33 a.m. ET by Tomi Kilgore

Alkermes upgraded to equal weight at Morgan Stanley

Sep. 5, 2019 at 10:09 a.m. ET by Tomi Kilgore

Biogen says it will not give up on Alzheimer’s after failed trials

Apr. 25, 2019 at 8:27 a.m. ET by Sarah Toy

Alkermes stock price target cut to $34 from $40 at Stifel Nicolaus

Feb. 15, 2019 at 7:55 a.m. ET by Tomi Kilgore

Breaking

Alkermes shares fall after FDA blocks antidepressant approval

Feb. 1, 2019 at 4:56 p.m. ET by Wallace Witkowski

Alkermes reports positive results in trial of schizophrenia treatment that reduces weight gain

Nov. 29, 2018 at 7:53 a.m. ET by Ciara Linnane

No Headlines Available

Other News
Press Releases

Where Does the Street Stand on Alkermes Ahead of the Lybalvi PDUFA Date?

May. 31, 2021 at 3:56 a.m. ET on TipRanks.com

Alkermes (ALKS) Up 3.6% Since Last Earnings Report: Can It Continue?

May. 28, 2021 at 11:32 a.m. ET on Zacks.com

Why Shares of Alkermes Rose 18% Last Month

May. 7, 2021 at 4:11 p.m. ET on Motley Fool

Want to Make Money in Biotech? Do This First

May. 7, 2021 at 6:17 a.m. ET on Motley Fool

Alkermes PLC (ALKS) Q1 2021 Earnings Call Transcript

Apr. 29, 2021 at 5:30 p.m. ET on Motley Fool

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS), Meridian Bioscience (VIVO) and Viking Therapeutics (VKTX)

Apr. 29, 2021 at 6:25 a.m. ET on SmarterAnalyst

Alkermes (ALKS) Q1 Earnings and Revenues Beat Estimates

Apr. 28, 2021 at 8:45 a.m. ET on Zacks.com

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Amgen (AMGN)

Apr. 28, 2021 at 8:05 a.m. ET on SmarterAnalyst

Why GlaxoSmithKline Stock Jumped Today

Apr. 15, 2021 at 4:24 p.m. ET on Motley Fool

Alkermes (ALKS) Inks Deal With Merck for Ovarian Cancer Study

Apr. 8, 2021 at 8:49 a.m. ET on Zacks.com

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), NeoGenomics (NEO) and Mirum Pharmaceuticals (MIRM)

Mar. 29, 2021 at 11:14 a.m. ET on SmarterAnalyst

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), NeoGenomics (NEO) and CymaBay Therapeutics (CBAY)

Mar. 29, 2021 at 11:08 a.m. ET on SmarterAnalyst

Analysts Have Conflicting Sentiments on These Healthcare Companies: Alkermes (ALKS), Alnylam Pharma (ALNY) and Bluebird Bio (BLUE)

Mar. 29, 2021 at 6:15 a.m. ET on SmarterAnalyst

Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates

Feb. 12, 2021 at 5:13 p.m. ET on Zacks.com

Alkermes (ALKS) Beats Q4 Earnings and Revenue Estimates

Feb. 11, 2021 at 8:35 a.m. ET on Zacks.com

Mizuho Securities Reiterates Their Buy Rating on Alkermes (ALKS)

Feb. 9, 2021 at 6:15 p.m. ET on SmarterAnalyst

What's in Store for Innoviva (INVA) This Earnings Season?

Feb. 2, 2021 at 8:52 a.m. ET on Zacks.com

Will Trikafta Drive Vertex's (VRTX) Revenues in Q4 Earnings?

Jan. 28, 2021 at 8:42 a.m. ET on Zacks.com

BioCryst (BCRX) Wins Japanese Approval for HAE Drug Orladeyo

Jan. 25, 2021 at 9:28 a.m. ET on Zacks.com

Ultragenyx's (RARE) IND for Wilson Disease Cleared by FDA

Jan. 22, 2021 at 9:02 a.m. ET on Zacks.com

No Headlines Available

Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.

Name	Chg %	Market Cap
AstraZeneca PLC ADR	-0.21%	$149.76B
Johnson & Johnson	0.26%	$445.7B
Sanofi ADR	0.89%	$134.2B
Bristol Myers Squibb Co.	0.02%	$146.81B
Pfizer Inc.	0.21%	$216.8B
Novartis AG ADR	-0.11%	$199.59B
Zogenix Inc.	-1.57%	$979.51M
Teva Pharmaceutical Industries Ltd. ADR	0.19%	$11.67B
Acorda Therapeutics Inc.	-1.85%	$35.3M

Competitor Data Provided By